)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
IRLAB Therapeutics (IRLAB) investor relations material
IRLAB Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary27 Aug, 2025
Executive summary
Advanced pipeline with five drug candidates for Parkinson's and CNS diseases, including three in clinical and two in preclinical development, with key milestones such as positive Phase I results for IRL757 and a new US patent for mesdopetam extending exclusivity into the 2040s.
Significant progress in patent protection, especially for Mestopetam, securing exclusivity into the mid-2040s in major markets.
Strengthened financial position through rights issues raising SEK 60 million and SEK 115.7 million, and expanded loan agreements.
Focused on advancing partnerships and licensing agreements to realize commercial value from the drug portfolio.
Leadership transition with CFO Viktor Siewertz departing and an interim CFO appointed.
Financial highlights
Cash and cash equivalents at period end were SEK 54 million, bolstered by rights issues, but down from SEK 98 million year-over-year.
Net sales for Jan–Jun 2025 were SEK 24 million, entirely from the Otsuka collaboration for IRL757, down from SEK 42.8 million year-over-year.
Operating loss widened to SEK -54.4 million, with a period loss of SEK -66.3 million and negative equity of SEK -27.7 million.
R&D costs accounted for 80% of total operating expenses in H1 2025.
External clinical costs decreased in May and June, with increased investment in IRL757 as new studies commence.
Outlook and guidance
Phase III initiation planned for Mestopetam, pending partnership.
IRL757 study in Parkinson’s apathy to begin dosing in Q4, with results expected in 18 months and first patient recruitment in Q4 2025.
11/17 preclinical work prioritized, aiming for Phase I start in late 2025 or early 2026.
Ongoing efforts to secure revenue-generating partnerships and licensing deals for advanced drug candidates.
Focus on optimizing development plans for pirepemat and IRL1117, with further studies planned.
Mesdopetam: What is the premium pricing potential?
Pirepemat: Detail the next study's design and goal
IRL1117: Explain its unique complication-free profile
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next IRLAB Therapeutics earnings date
Q3 202529 Oct, 2025
Next IRLAB Therapeutics earnings date
Q3 202529 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
)
Edge19 Sep 2025
American Express: An Empire of Plastic
How history, brand, and structure have steadily built American Express' moat, and why Warren Buffett still calls it a one-of-a-kind business.
Frequently asked questions
IRLAB Therapeutics AB is a research and development company developing drugs for the treatment of Parkinson's disease. IRLAB develops drugs that can stop or slow down the loss of neurons in the substantia nigra, where dopamine is produced. In Parkinson's disease, loss of these neurons leads to a gradual degeneration of the motor functions. These drugs will improve symptoms without dramatically increasing the risk of side effects.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage